Peptide Profile
Survodutide
What Is Survodutide?
Survodutide (also known by its development code BI 456906) is a GLP-1/glucagon dual agonist peptide designed by Zealand Pharma and developed clinically by Boehringer Ingelheim. Unlike single-target GLP-1 receptor agonists such as semaglutide or liraglutide, the survodutide peptide simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).
This dual-receptor approach is specifically intended to address conditions where appetite suppression alone is insufficient. The glucagon component of survodutide targets the liver directly, promoting hepatic fat oxidation and increasing energy expenditure — mechanisms that are particularly relevant for MASLD (metabolic dysfunction-associated steatotic liver disease) and its progressive form, MASH.
The survodutide Boehringer development programme has progressed rapidly, receiving FDA Breakthrough Therapy Designation for MASH. The compound is administered as a once-weekly subcutaneous injection with an estimated half-life of approximately 60–70 hours.
Compound Profile
Mechanism of Action
Survodutide’s mechanism relies on the coordinated activation of two receptor systems, each contributing distinct metabolic effects.
GLP-1 receptor activation drives appetite suppression, slowed gastric emptying, and improved glucose-dependent insulin secretion. These are the same pathways targeted by established GLP-1 receptor agonists used in appetite and weight management.
Glucagon receptor activation adds a differentiated dimension. Glucagon signalling in the liver increases hepatic fat oxidation, promotes glycogenolysis, and elevates resting energy expenditure. Preclinical pharmacology studies demonstrated that the survodutide glucagon component is essential for the compound’s superior weight loss and metabolic effects beyond what GLP-1 activation alone achieves. A 2025 preclinical study confirmed that hepatic GCGR activation is specifically required for the enhanced weight loss and metabolic improvements observed with this GLP-1 glucagon dual agonist class.
This dual-agonist design positions survodutide as more than a weight loss drug. The glucagon-mediated liver effects make it a potentially first-in-class treatment for MASH — a condition characterised by fat accumulation, inflammation, and fibrosis in the liver for which limited pharmacological options currently exist.
Zealand Pharma engineered the peptide backbone to achieve balanced potency at both receptors, while Boehringer Ingelheim has led the clinical development programme. Biomarker and pharmacological profiling studies have characterised survodutide’s receptor engagement, confirming robust dual activation at clinically relevant exposures.
MASLD / MASH Clinical Evidence
The most compelling clinical data for survodutide comes from its Phase 2 trial in MASH, published in the New England Journal of Medicine in 2024.
In this randomised, placebo-controlled study, participants with biopsy-confirmed MASH and liver fibrosis (stages F1–F3) received survodutide at escalating doses for 48 weeks. The results were striking:
- 83% resolution of steatohepatitis without worsening of fibrosis at the highest dose group — compared to 18.2% in the placebo arm
- Significant fibrosis improvement by at least one stage in a substantial proportion of treated participants
- Marked reductions in liver fat content as measured by MRI-derived proton density fat fraction
- Dose-dependent improvements in liver biomarkers including ALT and AST
These survodutide MASLD results represent some of the most robust liver-specific outcomes seen with any incretin-based therapy to date. The survodutide liver benefits are thought to derive primarily from the glucagon receptor component, which directly promotes hepatic fat oxidation — an effect that pure GLP-1 agonists do not replicate as effectively.
A separate Phase 1 study evaluated survodutide in patients with compensated cirrhosis (Child-Pugh A), confirming acceptable tolerability and pharmacokinetic profiles in this more advanced liver disease population.
Weight Loss Data
Survodutide weight loss data from Phase 2 trials has demonstrated clinically meaningful results across multiple study populations.
In the pivotal Phase 2 obesity trial published in The Lancet Diabetes & Endocrinology, adults with obesity (BMI ≥30, or ≥27 with comorbidities) received survodutide at various doses for 46 weeks:
- The highest dose group achieved mean weight loss of up to 18.7% of baseline body weight
- Weight reductions were dose-dependent and progressive throughout the treatment period
- Survodutide demonstrated weight loss comparable to or exceeding that observed with open-label semaglutide 2.4 mg in the same study
In a separate Phase 2 trial in people with type 2 diabetes, survodutide produced significant HbA1c reductions alongside meaningful weight loss, with dose-response effects observed across treatment arms. The dual mechanism — combining appetite suppression through GLP-1R with increased energy expenditure through GCGR — likely contributes to the magnitude of weight reduction achieved.
A 2025 systematic review and meta-analysis pooling data across survodutide trials confirmed consistent efficacy on both glycaemic control and weight loss in adults, with effect sizes that position it competitively among next-generation incretin-based therapies for fat loss.
Metabolic Effects
Beyond weight and liver outcomes, survodutide has demonstrated broad metabolic benefits in clinical trials:
Glycaemic control: In the Phase 2 type 2 diabetes study, survodutide GLP-1 and glucagon co-activation produced dose-dependent reductions in HbA1c, with the highest doses achieving reductions that were clinically comparable to established GLP-1 agonists. The dual mechanism may offer an advantage in patients with both obesity and diabetes, where glucagon’s effects on hepatic glucose output are balanced by the insulin-sensitising effects of weight loss and GLP-1R activation.
Lipid metabolism: Clinical data indicates improvements in triglyceride levels and other lipid parameters, consistent with the expected effects of both weight reduction and enhanced hepatic fat oxidation mediated by glucagon signalling.
Insulin sensitivity: Weight loss of the magnitude seen with survodutide (up to 18.7%) would be expected to produce meaningful improvements in insulin sensitivity, though dedicated insulin clamp studies have not been published at the time of writing.
Cardiovascular biomarkers: The SYNCHRONIZE cardiovascular outcomes trial (CVOT) has been designed to evaluate survodutide’s effects on major adverse cardiovascular events in people with obesity, reflecting the expectation that its metabolic benefits may translate to cardiovascular risk reduction.
Safety and Side Effects
The survodutide side effects profile observed across Phase 1 and Phase 2 trials is broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events representing the most common adverse effects.
Common side effects reported in clinical trials:
- Nausea — the most frequently reported adverse event, typically mild to moderate and most common during dose escalation
- Vomiting — also most prevalent during the titration phase
- Diarrhoea — occurring at rates similar to other GLP-1-based therapies
- Decreased appetite — generally considered a therapeutic effect rather than a side effect
- Constipation — reported by a minority of participants
Tolerability considerations: The Phase 1 programme established that a gradual dose-escalation strategy meaningfully reduces the incidence and severity of gastrointestinal side effects. Most adverse events were transient and diminished with continued treatment.
Glucagon-specific safety signals: Because survodutide activates the glucagon receptor, there is theoretical concern about hyperglycaemia. However, clinical data suggests that the GLP-1 component effectively counterbalances glucagon’s glycaemic effects, and no clinically significant hyperglycaemia has been reported in trials. Mild, transient increases in heart rate were observed in some dose groups, consistent with GLP-1 receptor agonist pharmacology.
The Phase 1 study in Japanese men with overweight/obesity confirmed a similar safety profile, supporting the generalisability of these findings across populations.
SYNCHRONIZE Phase 3 Programme
The survodutide Phase 3 clinical development programme, branded SYNCHRONIZE, represents one of the most ambitious Phase 3 programmes in the incretin space. It includes multiple pivotal trials:
SYNCHRONIZE-1: Phase 3 trial evaluating survodutide for weight management in adults with obesity without type 2 diabetes.
SYNCHRONIZE-2: Phase 3 trial in adults with obesity and type 2 diabetes. Published baseline characteristics confirm a large, multinational study population designed to support regulatory approval.
SYNCHRONIZE-CVOT: A cardiovascular outcomes trial assessing whether survodutide reduces major adverse cardiovascular events in people with established cardiovascular disease and obesity. The trial design, published in JACC: Heart Failure, reflects the regulatory expectation for cardiovascular safety and efficacy data.
SYNCHRONIZE-MASH: Phase 3 trials in MASH, building on the strong Phase 2 results. The FDA’s Breakthrough Therapy Designation for the MASH indication underscores the unmet medical need and the strength of existing clinical evidence.
If successful, the SYNCHRONIZE programme could position survodutide Boehringer Ingelheim as a first-in-class treatment for MASH and a competitive option for obesity — potentially differentiating it from the crowded GLP-1 agonist field through its liver-focused mechanism.
Research Limitations
While the survodutide evidence base is promising, several important limitations should be acknowledged:
- No Phase 3 efficacy data published yet: The strongest clinical evidence comes from Phase 2 trials. Phase 3 results from the SYNCHRONIZE programme are anticipated but not yet available. Phase 2 effect sizes do not always replicate in larger Phase 3 populations.
- Limited long-term safety data: The longest published treatment duration is 48 weeks. Long-term safety beyond one year — including effects on bone density, lean mass preservation, and potential thyroid signals — remains unknown.
- Histological endpoints require confirmation: The MASH Phase 2 trial used liver biopsy endpoints, which are the gold standard but involve inherent sampling variability. Phase 3 confirmation with larger sample sizes is needed.
- Glucagon-specific risks are not fully characterised: The long-term metabolic consequences of chronic glucagon receptor activation — including potential effects on amino acid metabolism, hepatic protein synthesis, and adrenal function — require further investigation.
- Head-to-head comparisons are limited: Direct comparisons with semaglutide exist only in a Phase 2 type 2 diabetes trial. No head-to-head data exists against tirzepatide, retatrutide, or resmetirom (the only currently approved MASH treatment).
- Population generalisability: Most trial participants were from Western populations. The Phase 1 Japanese study provides some cross-population data, but broader diversity is needed.
Verdict
Survodutide is one of the most promising peptides in the metabolic disease pipeline. Its GLP-1/glucagon dual agonist mechanism offers a differentiated approach that goes beyond appetite suppression — directly targeting the liver through glucagon receptor activation to promote hepatic fat clearance and increase energy expenditure.
The Phase 2 MASH results, with 83% steatohepatitis resolution, represent potentially best-in-class liver outcomes among incretin-based therapies. Combined with weight loss of up to 18.7% and meaningful glycaemic improvements, survodutide addresses the interconnected pathology of obesity, type 2 diabetes, and fatty liver disease.
However, evidence confidence remains moderate. Phase 3 data from the SYNCHRONIZE programme will be the decisive factor in determining whether survodutide’s Phase 2 promise translates to regulatory approval and clinical use. The compound’s safety profile appears manageable but requires longer-term characterisation, and head-to-head trials against established competitors would strengthen its positioning.
For researchers and clinicians tracking the next generation of metabolic therapies, survodutide — alongside retatrutide and tirzepatide — represents a meaningful evolution beyond first-generation GLP-1 agonists, with the liver-focused mechanism being its most compelling differentiator.
FAQ
What is survodutide?
Survodutide (BI 456906) is a GLP-1/glucagon dual agonist peptide developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both the GLP-1 receptor and the glucagon receptor, combining appetite suppression with increased hepatic fat oxidation and energy expenditure. It is currently in Phase 3 clinical trials for obesity and MASH.
How does survodutide differ from semaglutide?
While semaglutide is a pure GLP-1 receptor agonist, survodutide is a GLP-1 glucagon dual agonist that also activates the glucagon receptor. This additional glucagon component promotes direct hepatic fat burning and increases resting energy expenditure — mechanisms not present with semaglutide. This makes survodutide particularly relevant for liver diseases like MASLD and MASH.
What are the main survodutide side effects?
The most commonly reported survodutide side effects in clinical trials are gastrointestinal in nature: nausea, vomiting, diarrhoea, and decreased appetite. These are generally mild to moderate, most common during dose escalation, and tend to diminish with continued treatment. The safety profile is broadly similar to other GLP-1-based therapies.
What were the survodutide MASH trial results?
In the Phase 2 MASH trial published in the New England Journal of Medicine, survodutide achieved 83% resolution of steatohepatitis at the highest dose, compared to 18.2% with placebo. Significant improvements in fibrosis stage and liver fat content were also observed, representing some of the strongest liver-specific results for any incretin-based therapy.
How much weight loss does survodutide produce?
In the Phase 2 obesity trial, participants receiving the highest dose of survodutide achieved mean weight loss of up to 18.7% of baseline body weight over 46 weeks. Weight loss was dose-dependent and comparable to or exceeding open-label semaglutide 2.4 mg in the same study.
What is the SYNCHRONIZE programme?
SYNCHRONIZE is the survodutide Phase 3 clinical development programme run by Boehringer Ingelheim. It includes separate pivotal trials for obesity (with and without type 2 diabetes), MASH, and a cardiovascular outcomes trial. These trials will determine whether survodutide receives regulatory approval.
Is survodutide approved for clinical use?
No. As of early 2026, survodutide remains an investigational compound in Phase 3 trials. It has received FDA Breakthrough Therapy Designation for the MASH indication, but no regulatory approvals have been granted. Phase 3 results are anticipated in the coming years.
What is the survodutide half-life?
Survodutide has an estimated half-life of approximately 60–70 hours, which supports once-weekly subcutaneous administration. This pharmacokinetic profile was established through Phase 1 clinical studies in both Western and Japanese populations.
How does survodutide compare to retatrutide?
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while survodutide is a dual agonist (GLP-1/glucagon only). Retatrutide has shown greater weight loss in Phase 2 (over 24%), but survodutide is further advanced in clinical development and has stronger published liver-specific data. Both share the glucagon component that differentiates them from GLP-1/GIP agonists like tirzepatide.
Who developed survodutide?
The survodutide peptide backbone was designed by Zealand Pharma, a Danish biotechnology company specialising in peptide therapeutics. Boehringer Ingelheim, a German pharmaceutical company, leads the clinical development programme and holds the global rights. The Boehringer Ingelheim survodutide programme is one of the largest in the company’s metabolic disease portfolio.
References
- Zimmermann T et al. “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.” Mol Metab, 2022. PubMed
- Jungnik A et al. “Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.” Diabetes Obes Metab, 2023. PubMed
- Blüher M et al. “Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.” Diabetologia, 2024. PubMed
- le Roux CW et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol, 2024. PubMed
- Sanyal AJ et al. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” N Engl J Med, 2024. PubMed
- Lawitz EJ et al. “Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.” J Hepatol, 2024. PubMed
- Thomas L et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes Obes Metab, 2024. PubMed
- Kosiborod MN et al. “Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.” JACC Heart Fail, 2024. PubMed
- Wharton S et al. “Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.” Diabetes Obes Metab, 2026. PubMed
- Xiao YJ et al. “Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.” Diabetes Obes Metab, 2025. PubMed